Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 3/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1148099 | 0.84 | SMN1; SMN2 (0.64) | SMN1; SMN2LMNAPOLBTSHRRECQL | |
| SCHEMBL465225 | 0.82 | SMN1; SMN2 (0.77) | SMN1; SMN2LMNAPOLBTSHRRECQL | |
| SCHEMBL28583310 | 0.82 | SMN1; SMN2 (0.62) | SMN1; SMN2LMNAPOLBTSHRRECQL | |
| SCHEMBL6355623 | 0.82 | SMN1; SMN2 (0.62) | SMN1; SMN2LMNAPOLBTSHRRECQL | |
| SCHEMBL18210956 | 0.82 | TSHR (0.66) | SMN1; SMN2LMNAPOLBTSHRRECQL | |
| SCHEMBL14180427 | 0.81 | SMN1; SMN2 (0.65) | SMN1; SMN2LMNAPOLBTSHRRECQL | |
| SCHEMBL17111218 | 0.81 | SMN1; SMN2 (0.70) | SMN1; SMN2LMNAPOLBTSHRRECQL | |
| SCHEMBL17111209 | 0.79 | SMN1; SMN2 (0.58) | SMN1; SMN2LMNAPOLBTSHRRECQL | |
| SCHEMBL18358014 | 0.79 | SMN1; SMN2 (0.58) | SMN1; SMN2LMNAPOLBTSHRRECQL | |
| SCHEMBL14855841 | 0.79 | SMN1; SMN2 (0.68) | SMN1; SMN2LMNAPOLBTSHRRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884103-B2 | such as N-(4-Chloro-phenyl)-2-methyl-2-phenylmethanesulfonylamino-3-(4-[1,2,4]triazol-1-yl-phenoxy)-propionamide, used for controlling or preventing the infestation of plants by phytopathogenic microorganisms, especially fungi | SYNGENTA CROP PROTECTION, INC. (US) | 2011-02-08 | — | — | US | claimed |
| EP-1513802-B1 | ALPHA-SULFONYLAMINO-ACETONITRILES | SYNGENTA PARTICIPATIONS AG (CH) | 2009-08-19 | — | — | EP | claimed |
| US-7368479-B2 | Alpha-sulfonylamino-acetonitriles | SYNGENTA CROP PROTECTION, INC. (US) | 2008-05-06 | — | — | US | claimed |
| US-20070155748-A1 | N-sulfonyl-alpha-amino-acid derivatives | SYNGENTA CROP PROTECTION, INC. | 2007-07-05 | — | — | US | claimed |
| JP-2007504108-A | — | — | 2007-03-01 | — | — | JP | claimed |
| EP-1660441-A2 | N-SULFONYL-ALPHA-AMINO-ACID DERIVATIVES | Syngenta Participations AG (CH) | 2006-05-31 | — | — | EP | claimed |
| US-20050234125-A1 | Alpha-sulfonylamino-acetonitriles | SYNGENTA CROP PROTECTION AG (CH) | 2005-10-20 | — | — | US | claimed |
| EP-1513802-A1 | ALPHA-SULFONYLAMINO-ACETONITRILES | Syngenta Participations AG (CH) | 2005-03-16 | — | — | EP | claimed |
| WO-2005021490-A2 | N-SULFONYL-α-AMINO-ACID DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2005-03-10 | — | — | WO | claimed |
| WO-2004000797-A1 | ALPHA-SULFONYLAMINO-ACETONITRILES | SYNGENTA PARTICIPATIONS AG (CH) | 2003-12-31 | — | — | WO | claimed |
| EP-1147104-B1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMA (US) | 2012-03-14 | — | — | EP | disclosed |
| US-7884103-B2 | such as N-(4-Chloro-phenyl)-2-methyl-2-phenylmethanesulfonylamino-3-(4-[1,2,4]triazol-1-yl-phenoxy)-propionamide, used for controlling or preventing the infestation of plants by phytopathogenic microorganisms, especially fungi | SYNGENTA CROP PROTECTION, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| EP-1513802-B1 | ALPHA-SULFONYLAMINO-ACETONITRILES | SYNGENTA PARTICIPATIONS AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-7368479-B2 | Alpha-sulfonylamino-acetonitriles | SYNGENTA CROP PROTECTION, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20070155748-A1 | N-sulfonyl-alpha-amino-acid derivatives | SYNGENTA CROP PROTECTION, INC. | 2007-07-05 | — | — | US | disclosed |
| US-6492529-B1 | PHARMACEUTIC COMPOSITIONS FOR TREATING DISEASES OR PATHOLOGICAL CONDITIONS INVOLVING INFLAMMATION SUCH AS CHRONIC INFLAMMATORY DISEASES. | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | disclosed |
| US-6372773-B1 | TREATMENT OF INFLAMMATION, ARTHRITIS WITH UREA OR THIOUREA HETEROCYCLES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-04-16 | — | — | US | disclosed |
| US-6333325-B1 | ADMINISTERING PYRAZOLE DERIVATIVE OF UREA OR THIOUREA FOR THERAPY OF CYTOKINE MEDIATED DISEASE SUCH AS ACTUATE AND CHRONIC PAIN, CONTACT DERMATITIS, ATHEROSCLEROSIS, GLOMERULONEPHRITIS, REPERFUSION INJURY, BONE RESORPTION | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-12-25 | — | — | US | disclosed |
| US-6329415-B1 | INHIBIT RELEASE OF INFLAMMATORY CYTOKINES SUCH AS INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-12-11 | — | — | US | disclosed |
| US-6319921-B1 | FOR TREATMENT OF RHEUMATOID ARTHRITIS, MULTIPLE SCLEROSIS, GUILLAIN-BARRE SYNDROME, CROHN'S DISEASE ULCERATIVE COLITIS, PSORIASIS, GRAFT VERSUS HOST DISEASE, SYSTEMIC LUPUS ERYTHEMATOSUS AND DIABETES | BOERHINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234125-A1 | Alpha-sulfonylamino-acetonitriles | C3AR1, C1S, C5 | SMN1; SMN2 2294/4885LMNA 1938/4885POLB 4253/4885 |
| US-20070155748-A1 | N-sulfonyl-alpha-amino-acid derivatives | C3AR1, GLRA1, C5AR1 | SMN1; SMN2 3269/4885LMNA 3821/4885POLB 4770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.